Company Overview and News

 
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

13h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

 
Stocks slump on trade war

2018-09-10 thehindubusinessline
The escalating tariff war between the US and China had a ripple effect on Indian financial markets on Monday, roiling equity and forex markets alike.
AXB IDKQY HCTHY 532978 532215 AXBKY 535789 IBULHSGFIN AXBA BAJAJFINSV BAJFINANCE ZEEEY AXISBANK HCLTECH 505537 532281 BJJQY ZEEL 500034

 
Zee Entertainment Enterprises Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

 
ZEE Entertainment Enterprises appoints Rohit Gupta as CFO

2018-09-06 livemint
New Delhi: Television and media entertainment company Zee Entertainment Enterprises Ltd (ZEEL) announced the appointment of Rohit Gupta as chief financial officer. Gupta will report to Punit Goenka, managing director and chief executive officer, ZEEL.
532454 ZEEEY 505537 DCMSHRIRAM BHRQY BHARTIARTL ZEEL 523367

 
Zee Entertainment shares plunge to 20-month low

2018-09-06 thehindubusinessline
Shares of Zee Entertainment Enterprises Ltd plunged as much as 9.6 per cent to Rs 436.05, their lowest since December 2016. Morgan Stanley downgraded the stock to ‘underweight’ from ‘overweight’ and lowered the price target by 33 per cent to Rs 410. It has also cut FY-19/20 EBITDA estimates.
ZEEEY 505537 MS ZEEL

 
Zee Entertainment shares plummet after Morgan Stanley downgrade

2018-09-06 moneycontrol
The shares of Zee Entertainment Enterprises have fallen more than 8 percent and are trading near their 52-week levels after brokerages downgraded the stock.
ZEEEY 505537 MS ZEEL

 
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-09-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

 
Zee Entertainment Enterprises Limited - Appointment

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

 
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

 
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-08-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

 
Airtel and ZEE Entertainment sign up for content alliance

2018-08-20 livemint
New Delhi: Telecommunications company Bharti Airtel has announced a strategic content partnership with media and entertainment firm Zee Entertainment Enterprises Ltd (ZEEL) to “drive the over-the-top video streaming ecosystem in India”.
BALAJITELE 532454 ZEEEY 532382 505537 BHRQY BHARTIARTL ZEEL

 
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-08-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...